Stock Scorecard



Stock Summary for Gilead Sciences Inc (GILD)

Total Score

12 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for GILD

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GILD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GILD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for GILD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for GILD

Company Overview

Company Name Gilead Sciences Inc
Country USA
Description Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2022
Next Earnings Date 1/30/2023

Stock Price History

Last Day Price 86.26
Last Day Volume 0
Average Daily Volume 8,764,185
52-Week High 86.41
52-Week Low 55.27
Last Price to 52 Week Low 56.07 %

Valuation Measures

Trailing PE 32.36
Industry PE 221.48
Sector PE 93.04
5-Year Average PE 8.99
Free Cash Flow Ratio 112.03
Industry Free Cash Flow Ratio 9.58
Sector Free Cash Flow Ratio 37.55
Book Value Per Share Most Recent Quarter 16.81
Price to Book Ratio 4.98
Industry Price to Book Ratio 11.33
Sector Price to Book Ratio 15.35
Price to Sales Ratio Twelve Trailing Months 3.95
Industry Price to Sales Ratio Twelve Trailing Months 43.53
Sector Price to Sales Ratio Twelve Trailing Months 25.22

Share Statistics

Total Shares Outstanding 1,254,240,000
Market Capitalization 108,190,742,400
Institutional Ownership 0.00 %

Dividends

Ex-Dividend Date 12/14/2022
Last Dividend Amount 0.73
Current Dividend Amount 0.73
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 2.90
Trailing Annual Dividend Yield 3.43 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 21
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY -30.70 %
Annual Earnings Growth 4,960.98 %
Reported EPS Past Year 5.60
Reported EPS Prior Year 7.29
Net Income Twelve Trailing Months 3,334,000,000
Net Income Past Year 6,225,000,000
Net Income Prior Year 123,000,000
Quarterly Revenue Growth YOY -5.10 %
5-Year Revenue Growth 0.21 %

Balance Sheet

Total Cash Per Share 0.77
Total Cash Most Recent Quarter 961,000,000
Total Cash Past Year 6,520,000,000
Total Cash Prior Year 7,408,000,000
Net Cash Position Most Recent Quarter -24,262,000,000
Net Cash Position Past Year -20,175,000,000
Long Term Debt Past Year 26,695,000,000
Long Term Debt Prior Year 31,402,000,000
Total Debt Most Recent Quarter 25,223,000,000
Equity to Debt Ratio Past Year 0.44
Equity to Debt Ratio Most Recent Quarter 0.46
Current Ratio Most Recent Quarter 1.30
Total Stockholder Equity Past Year 21,069,000,000
Total Stockholder Equity Prior Year 18,202,000,000
Total Stockholder Equity Most Recent Quarter 21,081,000,000

Options

Put/Call Ratio 1.70
Has Options Options Chain
Liquidity Rating

Technical Analysis

MACD 3.95
MACD Signal 4.01
20-Day Bollinger Lower Band 59.27
20-Day Bollinger Middle Band 61.71
20-Day Bollinger Upper Band 64.15
Beta 0.44
RSI 79.24
50-Day SMA 63.95
200-Day SMA 61.72

System

Modified 11/26/2022 11:17:06 AM